Table 1.
Characteristics of all assessed patients in the EORTC and MBTB cohorts
| EORTC (n = 113) | MBTB (n = 255) | ||||
|---|---|---|---|---|---|
| Case status | Number | % | Number | % | |
| Age at diagnosis | <50 years | 56 | 50% | 85 | 33% |
| ≥50 years | 57 | 50% | 168 | 66% | |
| Tumor size | ≤2 cm | 3 | 3% | 51 | 20% |
| <2 cm to ≤5 | 68 | 60% | 142 | 56% | |
| >5 cm | 42 | 37% | 39 | 15% | |
| Unknown | 0 | 0 | 23 | 9% | |
| Nodal status | Negative | 42 | 37% | 88 | 35% |
| Positive | 71 | 63% | 142 | 56% | |
| Unknown | 0 | 0 | 25 | 10% | |
| Grade | 1-2 | 36 | 32% | 120 | 47% |
| 3 | 65 | 58% | 119 | 47% | |
| Unknown | 12 | 11% | 16 | 6% | |
| ERa | Negative | 113 | 100% | 255 | 100% |
| Positive | 0 | 0 | 0 | 0 | |
| PRb | Negative | 110 | 97% | 212 | 84% |
| Positive | 3 | 3% | 41 | 16% | |
| Unknown | 0 | 0 | 2 | <1% | |
| Her2c | Negative | 83 | 73% | 157 | 62% |
| Positive | 30 | 27% | 58 | 23% | |
| Unknown | 0 | 0 | 40 | 16% | |
Assessed cases were all invasive ductal carcinomas. aER-negative status defined as <10% of tumor cells stained positive for ER by IHC (EORTC) or <10 fmol/mg protein (ligand-binding assay; MBTB); bPR-negative status defined as <10% of tumor cells stained positive for PR by IHC (EORTC) or ≤15 fmol/mg protein (ligand-binding assay; MBTB); cHer2-positive status inferred based on microarray data (EORTC) or determined by an IHC score of 3 (MBTB).